FinnCap reissued their corporate rating on shares of Bioventix PLC (LON:BVXP) in a research note released on Tuesday morning. FinnCap currently has a GBX 2,600 ($34.20) price target on the biotechnology company’s stock.

Bioventix PLC (BVXP) opened at GBX 2,700 ($35.51) on Tuesday. Bioventix PLC has a 52 week low of GBX 26.51 ($0.35) and a 52 week high of GBX 2,950 ($38.80).

TRADEMARK VIOLATION WARNING: “Bioventix PLC (BVXP) Earns Corporate Rating from FinnCap” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at

The firm also recently declared a dividend, which was paid on Friday, November 10th. Stockholders of record on Thursday, October 26th were paid a GBX 71 ($0.93) dividend. This is a positive change from Bioventix PLC’s previous dividend of $20.00. The ex-dividend date of this dividend was Thursday, October 26th. This represents a dividend yield of 2.67%.

In other news, insider Ian James Nicholson sold 2,500 shares of Bioventix PLC stock in a transaction on Thursday, October 19th. The stock was sold at an average price of GBX 2,401 ($31.58), for a total value of £60,025 ($78,949.10).

About Bioventix PLC

Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.

Receive News & Ratings for Bioventix PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.